TeamDrive
RUS

Priority in drug procurement is considered the most effective to reduce imports

09 August 2018

GMP News

In 2018, the number of pharmaceutical companies believing that the most effective way to reduce the share of imported drugs is further restriction or ban on participation of foreign producers in public procurement, increased to 63%.

This information is provided by Deloitte, which this year conducted a survey among 52 Russian and foreign manufacturers of original drugs and generics, as well as pharmaceutical distributors. According to the analysis, for a year the priority of this measure increased, having risen in the corresponding rating from the fourth to the first position. A year earlier, the priority was to encourage foreign manufacturers to switch to full-cycle production by benefits and preferences. According to the results of the survey, only 29% of respondents now consider this measure effective, therefore, it moved down to the third position of the rating.

According to Oleg Berezin, the partner of Deloitte, the changes in the respondents’ assessments occurred most likely because the companies saw how effectively the “third wheel” rule has been working for state purchases since 2016. This rule excludes imported medicines from bidding, if there are proposals for the supply of at least two drugs produced in Russia. Since January 1, 2017, to obtain the status of a local product it is required to produce a finished dosage form in Russia.

Among other government measures to reduce the share of imported drugs are the additional procedures for registration of medicines approved and produced abroad. This year, 29% of respondents considered them effective.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more